CatalystFDA/Bio

Mirum finished enrollment in EXPAND, the Phase 3 that would stretch LIVMARLI beyond its approved Alagille and PFIC labels into biliary atresia and other rare cholestatic liver diseases. Primary endpoi

Mirum finished enrollment in EXPAND, the Phase 3 that would stretch LIVMARLI beyond its approved Alagille and PFIC labels into biliary atresia and other rare cholestatic liver diseases. Primary endpoi

MIRM

$82.24

+2.62%

What changed

Mirum finished enrollment in EXPAND, the Phase 3 that would stretch LIVMARLI beyond its approved Alagille and PFIC labels into biliary atresia and other rare cholestatic liver diseases. Primary endpoi

Why it matters

Mirum finished enrollment in EXPAND, the Phase 3 that would stretch LIVMARLI beyond its approved Alagille and PFIC labels into biliary atresia and other rare cholestatic liver diseases. Primary endpoi — impact context not separately stored; see What changed.

Sources

seekingalpha